LONDON--(BUSINESS WIRE)-- The potential value of Gabon’s healthcare market to drugmakers and medical device producers has showed a slightly decreasing trend for the second consecutive quarter. Expenditure growth rates are lower, as there is a touch of pessimism about the country’s long-term growth prospects, despite a stable political regime. However, flag iron ore mining shows potential and bright future.
In the Middle East and Africa pharmaceuticals risk/reward rating (RRR), Gabon scores 40 out of 100, down by 1.5 points compared to Q3 2012, due to a downward revision in the pharmaceutical market growth forecast, from 8.1% CAGR to a CAGR of 6.7%. The drop in Gabon’s RRR score means that the country’s pharmaceutical market, previously ranked 19th, is now the 20th most attractive in the region.
New discounted market research report “Gabon Pharmaceuticals and Healthcare Report Q4 2012” elaborated by Business Monitor International (BMI) is aimed at providing independent forecasts and competitive intelligence on Gabon’s pharmaceuticals and healthcare industry.
Title: Gabon Pharmaceuticals and Healthcare Report Q4 2012
Published: October, 2012
Price: US$ 1,175.00 US$ 995.00
More Discounted Market Research Reports by BMI Include:
- Serbia Pharmaceuticals and Healthcare Report Q3 2012
- Sudan and South Sudan Oil and Gas Report Q4 2012
- Austria Telecommunications Report Q4 2012
More new market research reports by BMI can be found at http://marketpublishers.com/members/businessmonitor/info.html
Source: The Market Publishers, Ltd.